Xspray Pharma launches SEK 83m rights issue to fund oncology pipeline

Xspray Pharma AB ( (SE:XSPRAY) ) just unveiled an update.

Xspray Pharma has published a disclosure document for a rights issue of approximately SEK 83 million with preferential rights for existing shareholders, which has been registered with the Swedish Financial Supervisory Authority and made available on the company’s and Aqurat’s websites. The capital raise, coordinated by Zonda Partners with legal advice from Advokatfirman Vinge, follows a set timetable in April 2026 for trading in subscription rights and paid subscribed shares, and is expected to support Xspray’s ongoing development of its oncology drug portfolio and reinforce its financial position ahead of key regulatory milestones.

The rights issue process includes an initial record date on 1 April 2026, followed by trading in subscription rights from 7–16 April and a subscription period running to 21 April, with the outcome expected around 23 April. This structured financing move underscores Xspray’s effort to secure funding from its existing shareholder base while it seeks to advance its pipeline of optimized cancer therapies and maintain its strategic positioning on Nasdaq Stockholm.

The most recent analyst rating on (SE:XSPRAY) stock is a Sell with a SEK26.00 price target. To see the full list of analyst forecasts on Xspray Pharma AB stock, see the SE:XSPRAY Stock Forecast page.

More about Xspray Pharma AB

Xspray Pharma AB is a Swedish pharmaceutical company developing improved versions of marketed protein kinase inhibitors for cancer treatment using its patent-protected HyNap technology platform. The company’s lead candidates, Dasynoc and XS003-nilotinib, are under FDA review, and it is building a portfolio that includes optimized versions of axitinib and cabozantinib, targeting the high-value oncology segment.

Average Trading Volume: 48,890

Technical Sentiment Signal: Sell

Current Market Cap: SEK1.15B

Learn more about XSPRAY stock on TipRanks’ Stock Analysis page.